30 closest matches · ranked by relevance
Healthy Volunteers · Hepatic Insufficiency · Diabetes Mellitus, Type 2
Primary: Pharmacokinetics: Area Under the Concentration Time Curve From Zero to Infinity (AUC[0-∞]) of LY2605541 — 85200; 67200; 64300; 66600 picomole*hours/liter (pmol*h/L)
Healthy · Hepatic Insufficiency
Primary: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC [0-∞]) of LY3502970 — 130; 132; 209; 611 nanogram *hour per…
Hepatic Insufficiency
Primary: Pharmacokinetics: Area Under the Concentration Time Curve (AUC) of LY2140023 and LY404039 — 1420; 1360; 836; 926 nanograms*hours per milliliter (ng*h/mL)
Hepatic Impairment · Healthy Volunteers
Primary: Maximum Plasma Concentration (Cmax) of PF-07081532 — 2236; 2121; 2230; 1536 nanogram per milliliter (ng/mL)
Depressive Disorder, Major
Primary: Pharmacokinetics: Area Under the Concentration Curve (AUC) — 601; 742; 961; 1020 hours times nanograms/milliliter
Hepatic Impairment
Primary: Maximum Plasma Concentration (Cmax) of PF-05221304 — 1220; 1591; 1433; 1592 Nanogram per milliliter (ng/mL)
Hepatic Insufficiency · Healthy
Primary: Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Imlunestrant — 58.0; 74.9; 87.6; 46.2 nanograms per milliliter (ng/mL)
Hepatic Insufficiency
Primary: Maximum Observed Plasma Concentration (Cmax) — 30.43; 26.96; 38.85 ng/mL
Diabetic Kidney Disease
Primary: Pharmacokinetic (PK) Parameter: AUCinf of Selonsertib and Its Metabolite GS-607509 — 3316.1; 3266.7; 2962.1; 2835.3 hr*ng/mL
Hepatic Insufficiency · Healthy
Primary: Area Under the Curve 0 to Infinity (AUC0-∞) — 10800; 13800; 16100; 19000 nmol*h/L
Advanced Solid Tumors · Hematologic Malignancies
Primary: Unbound AUC(0-last): Unbound Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Ixazomib — 9.6476; 7.3292…
Healthy Volunteer
Primary: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf) of Aleglitazar — 98.5; 113; 151 hours (h)*nanogram (ng)/milliliter (mL)
Schizophrenia
Primary: Unbound Brexpiprazole Area Under the Concentration Time Curve (AUC) Calculated to the Last Observable Concentration at Time t (AUCt,u) — 5.95; 4.87; 5.41; 4.28…
Moderate Hepatic Impairment
Primary: Maximum Plasma Concentration (Cmax) of Pexidartinib Following a Single Dose in Participants With Moderate Hepatic Impairment Compared to Healthy Participants — 1420…
Hepatic Insufficiency
Primary: Pharmacokinetics (PK): Area Under The Drug Concentration-Time Curve From Zero To Infinity (AUC[0-∞]) of Tirzepatide — 84300; 102000; 82000; 77000 nanogram*hour per…
Diabetes Mellitus, Type 2
Primary: Area Under the Plasma Concentration Versus Time Curve (AUC) From Hour 0 to Infinity (AUC0-∞) — 23.3; 24.9 µM*hr
Severe Hepatic Impairment · Healthy
Primary: Pharmacokinetic Parameters of MCI-186: Peak Drug Concentration (Cmax) — 347.6; 280.3 ng/mL
Anaemia
Primary: Part 1: Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC [0-infinity]) of GSK1278863 and Its Metabolites — 296.2407…
Diabetes Mellitus, Type 2
Primary: Pharmacokinetics: Maximum Observed Concentration (Cmax) — 84.5; 63.0; 58.1; 61.3 nanograms/milliliter (ng/mL)
Hepatic Impairment
Primary: Area Under the Plasma Concentration Time Curve From Time Zero to Infinity (AUC0-inf) of M2951 — 186; 232; 362 hour*nanogram per milliliter (h*ng/mL)
Nonalcoholic Steatohepatitis (NASH)
Primary: Pharmacokinetic (PK) Parameter: AUClast of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate) — 160.6…
Primary Biliary Cholangitis · Compensated Cirrhosis · Hepatic Impairment
Primary: Part A: Pharmacokinetic (PK) Parameter: Cmax of Seladelpar and Its Metabolites (M1, M2, and M3) — 182.0; 367.7; 359.2; 388.5 nanograms per milliliter (ng/mL)
Hepatic Insufficiency · Hepatic Impairment
Primary: Area Under the Concentration Versus Time Curve From Time 0 to Infinity (AUC0-inf) of Enlicitide — 540; 559 nM·hr
Hepatic Impairment
Primary: Maximum Observed Plasma Concentration (Cmax) for PF-04965842 — 1352; 1276; 1426 nanogram per milliliter (ng/mL)
Hepatic Insufficiency
Primary: Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Abemaciclib and Active Metabolites — 133; 109; 83.9; 156 nanograms per milliliter (ng/mL)
Cancer
Primary: Number of Patients With ALT (Alanine Transaminase) >=3x (Times) Upper Limit of Normal (ULN) — 11 participants
Impaired Liver Function
Primary: Maximum Blood Concentration (Cmax) — 827.5; 587.6; 1589.5; 974.0 ng/L
Advanced Cancer
Primary: Area Under Plasma Concentration Time Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib: Cycle 2 Day 1 — 3552; 2712; 3238; 2305 nanogram*hour per…
Hepatic Impairment · Healthy
Primary: Cmax — 538.1; 533.4; 429 ng/mL
Hepatic Impairment
Primary: Cmax for Serum Deferiprone and Deferiprone 3-O-glucuronide — 49.00; 36.26; 35.94; 69.03 ug/mL